Overview

A Study to Evaluate the Combination of Cetuximab and Chemotherapy as Neoadjuvant Therapy Followed Concomitant Chemoradiotherapy Plus Cetuximab in Locoregional Esophageal Carcinoma

Status:
Completed

Trial end date:
2012-11-01

Target enrollment:

Participant gender:

Summary

The purpose of the study is to determine efficacy ans safety of the combination of cetuximab and chemotherapy (docetaxel, cisplatin, 5-fluorouracil) as neoadjuvant therapy followed concomitant chemoradiotherapy (cisplatin) plus cetuximab in patients with a locoregional esophageal carcinoma

Phase:

Phase 2

Details

Lead Sponsor:

Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)

Collaborators:

Merck Sharp & Dohme Corp.
Sanofi

Treatments:

Cetuximab
Cisplatin
Docetaxel
Fluorouracil